Antimalarial drug combinations in vastly different settings.
Morrow
Richard H
RH
Department of International Health, Health Systems Program, Bloomberg School of Public Health, John Hopkins University, Baltimore, MD 21205, USA. rhmorrow@comcast.net
D000655:Amodiaquine / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000627:therapeutic use*; D002050:Burkina Faso; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004983:Ethanolamines / Q000627:therapeutic use*; D005449:Fluorenes / Q000627:therapeutic use*; D006801:Humans; D007214:Indonesia; D016778:Malaria, Falciparum / Q000188:drug therapy*; D016780:Malaria, Vivax / Q000188:drug therapy; D010963:Plasmodium falciparum / Q000235:genetics; D011739:Pyrimethamine / Q000627:therapeutic use*; D012008:Recurrence; D013413:Sulfadoxine / Q000627:therapeutic use*
D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine